WO2003103770A3 - METHOD OF CONTROLLED OVARIAN HYPERSTIMULATION AND PAHRMACEUTICAL KIT FOR THIS USE - Google Patents

METHOD OF CONTROLLED OVARIAN HYPERSTIMULATION AND PAHRMACEUTICAL KIT FOR THIS USE Download PDF

Info

Publication number
WO2003103770A3
WO2003103770A3 PCT/NL2003/000370 NL0300370W WO03103770A3 WO 2003103770 A3 WO2003103770 A3 WO 2003103770A3 NL 0300370 W NL0300370 W NL 0300370W WO 03103770 A3 WO03103770 A3 WO 03103770A3
Authority
WO
WIPO (PCT)
Prior art keywords
substance
dose
parenteral
ganirelix
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2003/000370
Other languages
French (fr)
Other versions
WO2003103770A2 (en
Inventor
Evert Johannes Bunschoten
Bennink Herman Jan Ti Coelingh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ares Trading SA
Original Assignee
Ares Trading SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to YUP-1050/04A priority Critical patent/RS105004A/en
Priority to MXPA04012246A priority patent/MXPA04012246A/en
Priority to NZ536984A priority patent/NZ536984A/en
Priority to MEP-393/08A priority patent/MEP39308A/en
Priority to JP2004510888A priority patent/JP2005530818A/en
Priority to ES03741621T priority patent/ES2399962T3/en
Priority to UAA200500168A priority patent/UA81251C2/en
Priority to US10/517,028 priority patent/US7815912B2/en
Priority to AU2003274929A priority patent/AU2003274929B2/en
Priority to EP03741621A priority patent/EP1511537B1/en
Priority to BR0305033-5A priority patent/BR0305033A/en
Priority to CA002488719A priority patent/CA2488719A1/en
Application filed by Ares Trading SA filed Critical Ares Trading SA
Priority to EA200401619A priority patent/EA009371B1/en
Publication of WO2003103770A2 publication Critical patent/WO2003103770A2/en
Publication of WO2003103770A3 publication Critical patent/WO2003103770A3/en
Priority to IL16552204A priority patent/IL165522A0/en
Priority to NO20045304A priority patent/NO20045304L/en
Priority to IS7586A priority patent/IS7586A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Selon un aspect, cette invention concerne une méthode d'hyperstimulation ovarienne contrôlée chez un sujet mammifère femelle. Cette méthode consiste dans la co-administration audit sujet femelle d'une substance présentant une activité hormonale folliculo-stimulante (substance FHS) en dose efficace pour stimuler un développement folliculaire multiple ; d'un antagoniste de gonadolibérine (GnRH) en quantité équivalente à une dose sous-cutanée quotidienne d'au moins 0,5 mg de ganirelix pour empêcher une poussée prématurée d'hormone lutéinisante; et une substance à base d'hormone lutéinisante en quantité efficace pour empêcher ou supprimer des symptômes de déficience d'hormone lutéinisante (LH) provoqués par l'administration de l'antagoniste de gonadolibérine; suivie par l'administration d'une substance induisant une méiose et une lutéinisation (substance ML) en dose efficace pour stimuler la reprise de la méiose et de la lutéinisation, la substance LH n'étant pas tirée de l'urine de femelles humaines. Selon un autre aspect, l'invention concerne une trousse pharmaceutique à utiliser avec une méthode d'hyperstimulation ovarienne, comprenant : au moins une dose posologique parentérale ou orale contenant une ou plusieurs substances FHS en quantité équivalant à une dose sous-cutanée de 0,5-25 mg de ganirelix; au moins une dose posologique parentérale d'antagonistes de GnRH en quantité équivalant à une dose sous-cutanée de 50-1500 I.U FHS3 ; au moins une dose posologique parentérale contenant un ou plusieurs antagonistes de GnRH en quantité équivalente à une dose sous-cutanée de 0,5-25 mg de ganirelix ; au moins une dose posologique parentérale contenant une quantité équivalente d'une dose sous-cutanée de 50-3000 I.U. de LH recombinante, la substance LH n'étant pas tirée de l'urine de femelles humaines.In one aspect, this invention relates to a method of controlled ovarian hyperstimulation in a female mammal subject. This method consists in the co-administration to said female subject of a substance exhibiting follicle-stimulating hormonal activity (substance FHS) in a dose effective for stimulating multiple follicular development; a gonadoliberin antagonist (GnRH) in an amount equivalent to a daily subcutaneous dose of at least 0.5 mg of ganirelix to prevent a premature flare-up of luteinizing hormone; and a luteinizing hormone substance in an amount effective to prevent or suppress symptoms of luteinizing hormone (LH) deficiency caused by administration of the gonadoliberin antagonist; followed by the administration of a substance inducing meiosis and luteinization (substance ML) in an effective dose to stimulate the resumption of meiosis and luteinization, the substance LH not being drawn from the urine of human females. According to another aspect, the invention relates to a pharmaceutical kit for use with an ovarian hyperstimulation method, comprising: at least one parenteral or oral dosage dose containing one or more FHS substances in an amount equivalent to a subcutaneous dose of 0, 5-25 mg of ganirelix; at least one parenteral dose of GnRH antagonists in an amount equivalent to a subcutaneous dose of 50-1500 I.U FHS3; at least one parenteral dosage containing one or more GnRH antagonists in an amount equivalent to a subcutaneous dose of 0.5-25 mg of ganirelix; at least one parenteral dosage containing an equivalent amount of a subcutaneous dose of 50-3000 I.U. of recombinant LH, the substance LH not being drawn from the urine of human females.

PCT/NL2003/000370 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method Ceased WO2003103770A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
BR0305033-5A BR0305033A (en) 2002-06-07 2003-06-06 Use of a substance having luteinizing hormone activity (lh substance), and pharmaceutical kit
NZ536984A NZ536984A (en) 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
MEP-393/08A MEP39308A (en) 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
JP2004510888A JP2005530818A (en) 2002-06-07 2003-06-06 Ovarian hyperstimulation control method and pharmaceutical kit used in the method
ES03741621T ES2399962T3 (en) 2002-06-07 2003-06-06 Ovarian controlled hyperstimulation method and pharmaceutical kit for use in this method
UAA200500168A UA81251C2 (en) 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
US10/517,028 US7815912B2 (en) 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
AU2003274929A AU2003274929B2 (en) 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
EP03741621A EP1511537B1 (en) 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
YUP-1050/04A RS105004A (en) 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
MXPA04012246A MXPA04012246A (en) 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method.
CA002488719A CA2488719A1 (en) 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
EA200401619A EA009371B1 (en) 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation pharmaceutical kit for use in such method
IL16552204A IL165522A0 (en) 2002-06-07 2004-12-02 Controlled ovarian hyperstimulation
NO20045304A NO20045304L (en) 2002-06-07 2004-12-03 Procedure for controlled ovarian hyperstimulation, as well as putty for use in the same
IS7586A IS7586A (en) 2002-06-07 2004-12-03 A method of controlling the great stimulation of the ovaries and a drug complex to use the method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02077221.6 2002-06-07
EP02077221 2002-06-07

Publications (2)

Publication Number Publication Date
WO2003103770A2 WO2003103770A2 (en) 2003-12-18
WO2003103770A3 true WO2003103770A3 (en) 2004-04-22

Family

ID=29724462

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2003/000370 Ceased WO2003103770A2 (en) 2002-06-07 2003-06-06 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method

Country Status (21)

Country Link
US (1) US7815912B2 (en)
EP (1) EP1511537B1 (en)
JP (1) JP2005530818A (en)
KR (1) KR20050058285A (en)
CN (1) CN1684737A (en)
AU (1) AU2003274929B2 (en)
BR (1) BR0305033A (en)
CA (1) CA2488719A1 (en)
EA (1) EA009371B1 (en)
ES (1) ES2399962T3 (en)
IL (1) IL165522A0 (en)
IS (1) IS7586A (en)
ME (1) MEP39308A (en)
MX (1) MXPA04012246A (en)
NO (1) NO20045304L (en)
NZ (1) NZ536984A (en)
PL (1) PL373991A1 (en)
RS (1) RS105004A (en)
UA (1) UA81251C2 (en)
WO (1) WO2003103770A2 (en)
ZA (1) ZA200409857B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE473746T1 (en) * 2007-01-08 2010-07-15 Pantarhei Bioscience Bv METHOD FOR TREATING OR PREVENTING INFERTILITY IN FEMALE MAMMALS AND PHARMACEUTICAL KIT FOR USING SUCH METHOD
BR112014001274A2 (en) 2011-07-18 2017-04-18 Arts Biologics As luteinizing hormone compound and pharmaceutical composition
US9216037B2 (en) 2013-06-21 2015-12-22 Previvo Genetics, Llc Uterine lavage for embryo retrieval
US20150272622A1 (en) 2011-12-22 2015-10-01 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo
US9282995B2 (en) * 2011-12-22 2016-03-15 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo
UA127283C2 (en) 2016-07-21 2023-07-12 Обсева С.А. THE METHOD OF USING AN ANTAGONIST OF OXYTOCIN TO PROMOTE EMBRYO IMPLANTATION AND PREVENT MISCARRIAGE
US20220323410A1 (en) 2019-09-03 2022-10-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
WO2021160597A1 (en) 2020-02-10 2021-08-19 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy
WO2026018221A1 (en) 2024-07-18 2026-01-22 ReproNovo SA Crystalline compositions for improving embryo implantation and methods of using the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0788799A2 (en) * 1996-02-07 1997-08-13 ASTA Medica Aktiengesellschaft LHRH-Antagonists in the treatment of fertility disorders
CN1199642A (en) * 1997-05-16 1998-11-25 Asta药物股份公司 LHRH-antagonists for the treatment of infertility
WO1998058657A1 (en) * 1997-06-20 1998-12-30 Akzo Nobel N.V. Gonadotropin releasing hormone antagonist
WO1999055357A1 (en) * 1998-04-23 1999-11-04 Asta Medica Aktiengesellschaft Method for the treatment of fertility disorders
WO2001000227A1 (en) * 1999-06-23 2001-01-04 Akzo Nobel N.V. Gonadotropin releasing hormone antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1353617A (en) * 1999-02-24 2002-06-12 诺沃挪第克公司 Treatment of infertility
US20030092628A1 (en) * 1999-06-23 2003-05-15 De Greef Henrik Johan Matthieu Maria Gonadotropin releasing hormone antagonist
DE60231892D1 (en) * 2001-09-12 2009-05-20 Serono Lab USE OF LH FOR CONTROLLED OVARIAN HYPERSTIMULATION
AU2002358346A1 (en) 2001-12-21 2003-07-15 Pantarhei Bioscience B.V. Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0788799A2 (en) * 1996-02-07 1997-08-13 ASTA Medica Aktiengesellschaft LHRH-Antagonists in the treatment of fertility disorders
CN1199642A (en) * 1997-05-16 1998-11-25 Asta药物股份公司 LHRH-antagonists for the treatment of infertility
WO1998058657A1 (en) * 1997-06-20 1998-12-30 Akzo Nobel N.V. Gonadotropin releasing hormone antagonist
WO1999055357A1 (en) * 1998-04-23 1999-11-04 Asta Medica Aktiengesellschaft Method for the treatment of fertility disorders
WO2001000227A1 (en) * 1999-06-23 2001-01-04 Akzo Nobel N.V. Gonadotropin releasing hormone antagonist

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AL-INANY HESHAM ET AL: "GnRH antagonist in assisted reproduction: A Cochrane review", HUMAN REPRODUCTION (OXFORD), vol. 17, no. 4, April 2002 (2002-04-01), &, pages 874 - 885, XP009020113, ISSN: 0268-1161 *
BELAISCH-ALLART J ET AL: "Recommendations of good practice: Medicines that induce ovulation (June 2003)", GYNECOLOGIE OBSTETRIQUE FERTILITE 2003 FRANCE, vol. 31, no. 7-8, 2003, pages 676 - 686, XP001155766, ISSN: 1297-9589 *
BURGUES S ET AL: "THE EFFECTIVENESS AND SAFETY OF RECOMBINANT HUMAN LH TO SUPPORT FOLLICULAR DEVELOPMENT INDUCED BY RECOMBINANT HUMAN FSH IN WHO GROUP I ANOVULATION: EVIDENCE FROM A MULTICENTRE STUDY IN SPAIN", HUMAN REPRODUCTION, IRL PRESS, OXFORD, GB, vol. 16, no. 12, 2001, pages 2525 - 2532, XP001057228, ISSN: 0268-1161 *
FAUSER B C ET AL: "ENDOCRINE PROFILES AFTER TRIGGERING OF FINAL OOCYTE MATURATION WITH GNRH AGONIST AFTER COTREATMENT WITH TH GNRH ANTAGONIST GANIRELIX DURING OVARIAN HYPERSTIMULATION FOR IN VITRO FERTILIZATION", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, NEW YORK, NY, US, vol. 87, no. 2, February 2002 (2002-02-01), pages 709 - 715, XP008022669, ISSN: 0021-972X *
HUGUES J-N ET AL: "LES PROTOCOLES DE STIMULATION OVARIENNE EN VUE DE FECONDATION IN VITRO: EVOLUTION AU COURS DES DERNIERES ANNEES. QU'EN EST-IL EN 2003? EVOLUTION OF PROTOCOLS FOR OVARIAN STIMULATION IN VITRO FERTILIZATION IN THE PAST YEARS: WHAT'S IN STORE IN 2003?", MTE. MEDECINE THERAPEUTIQUE ENDOCRINOLOGIE, JOHN LIBBEY EUROTEXT, MONTROUGE, FR, vol. 5, no. 1, 2003, pages 7 - 17, XP001155774, ISSN: 1295-9359 *
JUST A ET AL: "Ovarian stimulation and ovulation induction is assisted reproduction", JOURNAL FUR FERTILITAT UND REPRODUKTION 2002 AUSTRIA, vol. 12, no. 4, 2002, pages 20 - 24, XP009020112, ISSN: 1019-066X *
KRUSCHE C A ET AL: "The progesterone antagonist onapristone retards the advanced endometrial transformation after gonadotropin stimulation in rabbits", STEROIDS, BUTTERWORTH-HEINEMANN, STONEHAM, MA, US, vol. 65, no. 10-11, October 2000 (2000-10-01), pages 773 - 782, XP004224005, ISSN: 0039-128X *
LISI FRANCO ET AL: "Use of recombinant follicle-stimulating hormone (Gonal F) and recombinant luteinizing hormone (Luveris) for multiple follicular stimulation in patients with a suboptimal response to in vitro fertilization.", FERTILITY AND STERILITY, vol. 79, no. 4, April 2003 (2003-04-01), &, pages 1037 - 1038, XP001179215, ISSN: 0015-0282 *
LUDWIG M ET AL: "Developments in drugs for ovarian stimulation.", BEST PRACTICE & RESEARCH. CLINICAL OBSTETRICS & GYNAECOLOGY. APR 2003, vol. 17, no. 2, April 2003 (2003-04-01), pages 231 - 247, XP009020046, ISSN: 1521-6934 *
LUDWIG M ET AL: "Modern aspects of reproduction medicine", GYNAKOLOGE 2002 GERMANY, vol. 35, no. 9, 2002, pages 861 - 866, XP001155767, ISSN: 0017-5994 *
RON-EL R ET AL: "INDUCTION OF OVULATION AFTER GNRH ANTAGONISTS", HUMAN REPRODUCTION UPDATE, OXFORD UNIVERSITY PRESS, OXFORD, GB, vol. 6, no. 4, July 2000 (2000-07-01), pages 318 - 321, XP001119287 *
WIKLAND M ET AL: "A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI", HUMAN REPRODUCTION (OXFORD), vol. 16, no. 8, August 2001 (2001-08-01), &, pages 1676 - 1681, XP009020114, ISSN: 0268-1161 *

Also Published As

Publication number Publication date
CN1684737A (en) 2005-10-19
NZ536984A (en) 2008-01-31
US7815912B2 (en) 2010-10-19
MEP39308A (en) 2011-02-10
EA200401619A1 (en) 2005-06-30
UA81251C2 (en) 2007-12-25
BR0305033A (en) 2004-11-09
NO20045304L (en) 2005-02-07
IS7586A (en) 2004-12-03
EP1511537A2 (en) 2005-03-09
RS105004A (en) 2007-02-05
ZA200409857B (en) 2006-02-22
ES2399962T3 (en) 2013-04-04
PL373991A1 (en) 2005-09-19
MXPA04012246A (en) 2005-04-08
KR20050058285A (en) 2005-06-16
CA2488719A1 (en) 2003-12-18
US20050235374A1 (en) 2005-10-20
IL165522A0 (en) 2006-01-15
EA009371B1 (en) 2007-12-28
AU2003274929A1 (en) 2003-12-22
WO2003103770A2 (en) 2003-12-18
AU2003274929B2 (en) 2008-04-10
EP1511537B1 (en) 2012-11-21
JP2005530818A (en) 2005-10-13

Similar Documents

Publication Publication Date Title
Vrachnis et al. The oxytocin‐oxytocin receptor system and its antagonists as tocolytic agents
Schneider et al. Estradiol and the neuroendocrine control of LH release in vitro
US5464854A (en) Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
Melis et al. Overview of elagolix for the treatment of endometriosis
NO20024586D0 (en) Method and preparations to prevent hormone-induced side effects
DK1317419T3 (en) Cyanophenoxycarboxylic acid compounds and compositions to deliver active agents
WO2003103770A3 (en) METHOD OF CONTROLLED OVARIAN HYPERSTIMULATION AND PAHRMACEUTICAL KIT FOR THIS USE
US7288517B2 (en) Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists
Kovács et al. Structure–activity study on the LH-and FSH-releasing and anticancer effects of gonadotropin-releasing hormone (GnRH)-III analogs
Bagatell et al. Single-dose administration of the gonadotropin-releasing hormone antagonist, Nal-Lys (antide) to healthy men
Deng et al. PYY inhibits CCK-stimulated pancreatic secretion through the area postrema in unanesthetized rats
RU2181598C2 (en) Recovery of tonic secretion of ovarian estrogen for prolonged therapeutic schemes
Bastos et al. Alpha-adrenergic agonists inhibit the dipsogenic effect of angiotensin II by their stimulation of atrial natriuretic peptide release
Safieh-Garabedian et al. Hyperalgesia induced by low doses of thymulin injections: possible involvement of prostaglandin E2
Lew et al. Peptidases that degrade gonadotropin‐releasing hormone: influence on LH secretion in the ewe
Walters et al. Luteinizing hormone-releasing hormone I (LHRH-I) and its metabolite in peripheral tissues
EA200200801A1 (en) Use of follicle-stimulating hormone (FSH) for the treatment of infertility
ATE277639T1 (en) COMPOSITIONS OF ADENOSINE A1 AGONISTS AND 5HT3 AGONISTS
dos Santos Moreira et al. Inhibition of pilocarpine-induced salivation in rats by central noradrenaline
US6437093B1 (en) Methods of treatment comprising administration of Substance P
Bagatell et al. Dose effects of the gonadotropin-releasing hormone antagonist, Nal-Glu, combined with testosterone enanthate on gonadotropin levels in normal men
CA2444980A1 (en) Single dose aromatase inhibitor for treating infertility
CA2472309A1 (en) Multiple dose aromatase inhibitor for treating infertility
BE1002256A3 (en) DRUGS.
Gulliford Opioid-induced sexual dysfunction

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-1050/04

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1-2004-501993

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2003741621

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003274929

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 165522

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 536984

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004/09857

Country of ref document: ZA

Ref document number: 2488719

Country of ref document: CA

Ref document number: 3866/DELNP/2004

Country of ref document: IN

Ref document number: 200409857

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/012246

Country of ref document: MX

Ref document number: 373991

Country of ref document: PL

Ref document number: 2004510888

Country of ref document: JP

Ref document number: 1020047019890

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200401619

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 20038183900

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003741621

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10517028

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020047019890

Country of ref document: KR